中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (3): 191-203.doi: 10.35541/cjd.20220652
中华医学会皮肤性病学分会银屑病专业委员会
收稿日期:
2022-09-13
修回日期:
2023-01-09
发布日期:
2023-03-06
通讯作者:
陈翔;张学军
E-mail:chenxiangck@126.com; ayzxj@vip.sina.com
Committee on Psoriasis, Chinese Society of Dermatology
Received:
2022-09-13
Revised:
2023-01-09
Published:
2023-03-06
Contact:
Chen Xiang; Zhang Xuejun
E-mail:chenxiangck@126.com; ayzxj@vip.sina.com
摘要: 【摘要】 银屑病是一种慢性、复发性、炎症性和系统性疾病,给患者带来沉重负担,影响患者生活质量。随着多种生物制剂不断应用于临床,银屑病患者有更多的治疗选择,但综合治疗目标如何评估尚未达成一致意见。达标治疗策略需要考虑多个维度的治疗结果,制定长期管理目标和定期评估治疗情况。本共识根据国内外最新共识及指南、研究数据和临床经验,结合问卷调查和专家组的讨论结果,重点阐述了清除皮损、提高患者生活质量、筛查和管理银屑病共病和保障用药安全性这4个维度的短期和长期银屑病生物制剂治疗的综合管理目标,描述了实施方法、评估时间、治疗监测和方案调整,旨在最大程度实现银屑病全面管理的目标,供临床参考。
中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识[J]. 中华皮肤科杂志, 2023,56(3):191-203. doi:10.35541/cjd.20220652
Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents[J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.doi:10.35541/cjd.20220652
[1] | Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis[J]. Lancet, 2021,397(10281):1301⁃1315. doi: 10.1016/S0140⁃6736(20)32549⁃6. |
[2] | Shen M, Xiao Y, Jing D, et al. Associations of combined lifestyle and genetic risks with incident psoriasis: a prospective cohort study among UK Biobank participants of European ancestry[J]. J Am Acad Dermatol, 2022,87(2):343⁃350. doi: 10.1016/j.jaad.2022.04.006. |
[3] | Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies[J]. J Eur Acad Dermatol Venereol, 2014,28(3):333⁃337. doi: 10.1111/jdv.12106. |
[4] | Snast I, Reiter O, Atzmony L, et al. Psychological stress and psoriasis: a systematic review and meta⁃analysis[J]. Br J Dermatol, 2018,178(5):1044⁃1055. doi: 10.1111/bjd.16116. |
[5] | Egeberg A, Griffiths C, Williams HC, et al. Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults[J]. Br J Dermatol, 2020,183(1):128⁃138. doi: 10.1111/bjd.18622. |
[6] | Gisondi P, Talamonti M, Chiricozzi A, et al. Treat⁃to⁃target approach for the management of patients with moderate⁃to⁃severe plaque psoriasis: consensus recommendations[J]. Dermatol Ther (Heidelb), 2021,11(1):235⁃252. doi: 10.1007/s13555⁃020⁃00475⁃8. |
[7] | Griffiths C, Augustin M, Naldi L, et al. Patient⁃dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real⁃world multinational survey[J]. J Eur Acad Dermatol Venereol, 2018,32(9):1523⁃1529. doi: 10.1111/jdv. 14937. |
[8] | Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus[J]. Arch Dermatol Res, 2011,303(1):1⁃10. doi: 10.1007/s00403⁃010⁃1080⁃1. |
[9] | Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review[J]. JAMA, 2020,323(19):1945⁃1960. doi: 10.1001/jama.2020.4006. |
[10] | Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate⁃to⁃severe plaque psoriasis[J]. Br J Dermatol, 2018,178(2):509⁃519. doi: 10.1111/bjd.16102. |
[11] | Grine L, de la Brassinne M, Ghislain PD, et al. A Belgian consensus on the definition of a treat⁃to⁃target outcome set in psoriasis management[J]. J Eur Acad Dermatol Venereol, 2020,34(4):676⁃684. doi: 10.1111/jdv.16104. |
[12] | Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate⁃to⁃severe plaque psoriasis[J]. J Eur Acad Dermatol Venereol, 2017,31(5):774⁃790. doi: 10. 1111/jdv.14114. |
[13] | Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique[J]. J Adv Nurs, 2000,32(4):1008⁃1015. |
[14] | Jones J, Hunter D. Consensus methods for medical and health services research[J]. BMJ, 1995,311(7001):376⁃380. doi: 10. 1136/bmj.311.7001.376. |
[15] | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2018完整版)[J]. 中华皮肤科杂志, 2019,52(10):667⁃710. doi: 10.35541/cjd.20190847. |
[16] | Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis[J]. J Am Acad Dermatol, 2012,66(3):369⁃375. doi: 10.1016/j.jaad.2011.01.022. |
[17] | Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician′s Global Assessment[J]. J Am Acad Dermatol, 2004,51(4):563⁃569. doi: 10.1016/j.jaad.2004.04.012. |
[18] | Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature[J]. J Eur Acad Dermatol Venereol, 2010,24(Suppl 2):10⁃16. doi: 10.1111/j.1468⁃3083.2009.03562.x. |
[19] | Wu AG, Conway J, Barazani L, et al. Is clear always clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician′s Global Assessment (PGA) in psoriasis clearance[J]. Dermatol Ther (Heidelb), 2020,10(5):1155⁃1163. doi: 10. 1007/s13555⁃020⁃00435⁃2. |
[20] | Rattanakaemakorn P, Triyangkulsri K, Iamsumang W, et al. 308⁃nm excimer lamp vs. combination of 308⁃nm excimer lamp and 10% liquor carbonis detergens in patients with scalp psoriasis: a randomized, single⁃blinded, controlled trial[J]. Front Med (Lausanne), 2021,8:677948. doi: 10.3389/fmed.2021. 677948. |
[21] | Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate⁃to⁃severe scalp psoriasis: results of a 24⁃week, randomized, double⁃blind, placebo⁃controlled phase 3b study[J]. J Am Acad Dermatol, 2017,77(4):667⁃674. doi: 10.1016/j.jaad.2017.05.033. |
[22] | Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial[J]. J Am Acad Dermatol, 2017,76(1):70⁃80. doi: 10.1016/j.jaad.2016.07.058. |
[23] | Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate⁃to⁃severe plaque psoriasis and non⁃pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER⁃1, UNCOVER⁃2 and UNCOVER⁃3)[J]. J Eur Acad Dermatol Venereol, 2017,31(10):1686⁃1692. doi: 10. 1111/jdv.14237. |
[24] | Merola JF, Bleakman AP, Gottlieb AB, et al. The Static Physician′s Global Assessment of Genitalia: a clinical outcome measure for the severity of genital psoriasis[J]. J Drugs Dermatol, 2017,16(8):793⁃799. |
[25] | Tan ES, Chong WS, Tey HL. Nail psoriasis: a review[J]. Am J Clin Dermatol, 2012,13(6):375⁃388. doi: 10.2165/11597000⁃000000000⁃00000. |
[26] | Neuhauser R, Eyerich K, Boehner A. Generalized pustular psoriasis⁃Dawn of a new era in targeted immunotherapy[J]. Exp Dermatol, 2020,29(11):1088⁃1096. doi: 10.1111/exd.14171. |
[27] | Burden AD, Choon SE, Gottlieb AB, et al. Clinical disease measures in generalized pustular psoriasis[J]. Am J Clin Dermatol, 2022,23(Suppl 1):39⁃50. doi: 10.1007/s40257⁃021⁃00653⁃0. |
[28] | Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double⁃blind, placebo⁃controlled study[J]. Br J Dermatol, 2001,145(4):546⁃553. doi: 10.1046/j.1365⁃2133.2001.04411.x. |
[29] | Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate⁃to⁃severe palmoplantar pustular psoriasis: results of the 2PRECISE study[J]. J Am Acad Dermatol, 2019,80(5):1344⁃1352. doi: 10.1016/j.jaad.2019.01.066. |
[30] | Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin⁃36 pathway for the treatment of generalized pustular psoriasis[J]. N Engl J Med, 2019,380(10):981⁃983. doi: 10. 1056/NEJMc1811317. |
[31] | Carrasquillo OY, Pabón⁃Cartagena G, Falto⁃Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: a systematic review[J]. J Am Acad Dermatol, 2020,83(1):151⁃158. doi: 10. 1016/j.jaad.2020.03.073. |
[32] | Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires[J]. Ann Rheum Dis, 2013,72(5):736⁃740. doi: 10.1136/annrheumdis⁃2012⁃201706. |
[33] | Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis[J]. J Eur Acad Dermatol Venereol, 2011,25(12):1409⁃1414. doi: 10.1111/j.1468⁃3083.2011.03985.x. |
[34] | Coates LC, Corp N, van der Windt DA, et al. GRAPPA treatment recommendations: 2021 update[J]. J Rheumatol, 2022,49(6 Suppl 1):52⁃54. doi: 10.3899/jrheum.211331. |
[35] | Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis[J]. Arthritis Rheumatol, 2016,68(5):1060⁃1071. doi: 10.1002/art.39573. |
[36] | 《中国关节病型银屑病诊疗共识(2020)》编写委员会专家组. 中国关节病型银屑病诊疗共识(2020)[J]. 中华皮肤科杂志, 2020,53(8):585⁃595. doi: 10.35541/cjd.20200369. |
[37] | McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double⁃blind, parallel⁃group, randomised, active⁃controlled, phase 3b trial[J]. Lancet, 2020,395(10235):1496⁃1505. doi: 10.1016/S0140⁃6736(20)30564⁃X. |
[38] | Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT⁃PsA 2[J]. Ann Rheum Dis, 2021,80(3):312⁃320. doi: 10.1136/annrheumdis⁃2020⁃218870. |
[39] | Eberl G, Studnicka⁃Benke A, Hitzelhammer H, et al. Development of a disease activity index for the assessment of reactive arthritis (DAREA)[J]. Rheumatology (Oxford), 2000,39(2):148⁃155. doi: 10.1093/rheumatology/39.2.148. |
[40] | Aouad K, Moysidou G, Rakotozafiarison A, et al. Outcome measures used in psoriatic arthritis registries and cohorts: a systematic literature review of 27 registries or 16,183 patients[J]. Semin Arthritis Rheum, 2021,51(4):888⁃894. doi: 10.1016/j.semarthrit.2021.06.008. |
[41] | Gonçalves R, de Almeida Martins LM, de Ataide Mariz H, et al. DAPSA versus cDAPSA: do we need to use CRP?[J]. Ann Rheum Dis, 2020,79(11):e142. doi: 10.1136/annrheumdis⁃2019⁃215960. |
[42] | Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)[J]. Ann Rheum Dis, 2013,72(6):986⁃991. doi: 10.1136/annrheumdis⁃2012⁃201341. |
[43] | Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score[J]. Ann Rheum Dis, 2016,75(5):811⁃818. doi: 10.1136/annrheumdis⁃2015⁃207507. |
[44] | Lubrano E, De Socio A, Perrotta FM. Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: a cross⁃sectional analysis of a longitudinal cohort[J]. J Rheumatol, 2017,44(8):1159⁃1164. doi: 10.3899/jrheum.170112. |
[45] | Coates LC, Helliwell PS. Defining low disease activity states in psoriatic arthritis using novel composite disease instruments[J]. J Rheumatol, 2016,43(2):371⁃375. doi: 10.3899/jrheum.150826. |
[46] | Perruccio AV, Got M, Li S, et al. Treating psoriatic arthritis to target: defining the psoriatic arthritis disease activity score that reflects a state of minimal disease activity[J]. J Rheumatol, 2020,47(3):362⁃368. doi: 10.3899/jrheum.181472. |
[47] | Coates LC, Gladman DD, Nash P, et al. Secukinumab provides sustained PASDAS⁃defined remission in psoriatic arthritis and improves health⁃related quality of life in patients achieving remission: 2⁃year results from the phase III FUTURE 2 study[J]. Arthritis Res Ther, 2018,20(1):272. doi: 10.1186/s13075⁃018⁃1773⁃y. |
[48] | Kitchen H, Cordingley L, Young H, et al. Patient⁃reported outcome measures in psoriasis: the good, the bad and the missing![J]. Br J Dermatol, 2015,172(5):1210⁃1221. doi: 10.1111/bjd.13691. |
[49] | Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean?[J]. J Invest Dermatol, 2005,125(4):659⁃664. doi: 10.1111/j.0022⁃202X.2005.23621.x. |
[50] | Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy⁃Fatigue (FACIT⁃F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)[J]. Arthritis Care Res (Hoboken), 2011,63(Suppl 11):S64⁃S85. doi: 10.1002/acr.20577. |
[51] | Ware JE Jr, Sherbourne CD. The MOS 36⁃item short⁃form health survey (SF⁃36). I. Conceptual framework and item selection[J]. Med Care, 1992,30(6):473⁃483. |
[52] | Dauden E, Blasco AJ, Bonanad C, et al. Position statement for the management of comorbidities in psoriasis[J]. J Eur Acad Dermatol Venereol, 2018,32(12):2058⁃2073. doi: 10.1111/jdv.15177. |
[53] | Elmets CA, Leonardi CL, Davis D, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities[J]. J Am Acad Dermatol, 2019,80(4):1073⁃1113. doi: 10.1016/j.jaad.2018.11. 058. |
[54] | Zigmond AS, Snaith RP. The hospital anxiety and depression scale[J]. Acta Psychiatr Scand, 1983,67(6):361⁃370. doi: 10.1111/j.1600⁃0447.1983.tb09716.x. |
[55] | Ewing JA. Detecting alcoholism. The CAGE questionnaire[J]. JAMA, 1984,252(14):1905⁃1907. doi: 10.1001/jama.252.14.1905. |
[56] | Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis[J]. J Am Acad Dermatol, 2017,76(2):290⁃298. doi: 10.1016/j.jaad.2016.10.017. |
[57] | Gladman DD, Poulin Y, Adams K, et al. Treating psoriasis and psoriatic arthritis: position paper on applying the treat⁃to⁃target concept to canadian daily practice[J]. J Rheumatol, 2017,44(4):519⁃534. doi: 10.3899/jrheum.161473. |
[58] | Belinchón Romero I, Dauden E, Ferrándiz Foraster C, et al. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document[J]. Ann Med, 2021,53(1):1727⁃1736. doi: 10.1080/07853890.2021.1986637. |
[59] | Daudén E, Puig L, Ferrándiz C, et al. Consensus document on the evaluation and treatment of moderate⁃to⁃severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology[J]. J Eur Acad Dermatol Venereol, 2016,30(Suppl 2):1⁃18. doi: 10.1111/jdv.13542. |
[60] | Mrowietz U, Warren RB, Leonardi CL, et al. Network meta⁃analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method[J]. J Eur Acad Dermatol Venereol, 2021,35(5):1161⁃1175. doi: 10.1111/jdv.17130. |
[61] | Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real⁃world, population⁃based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)[J]. Br J Dermatol, 2020,182(5):1158⁃1166. doi: 10.1111/bjd.18333. |
[62] | Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis[J]. N Engl J Med, 2021,385(26):2431⁃2440. doi: 10.1056/NEJMoa2111563. |
[63] | Lo Y, Tsai TF. Updates on the treatment of erythrodermic psoriasis[J]. Psoriasis (Auckl), 2021,11:59⁃73. doi: 10.2147/PTT.S288345. |
[64] | Okubo Y, Mabuchi T, Iwatsuki K, et al. Long⁃term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open⁃label, phase 3 study (UNCOVER⁃J)[J]. J Eur Acad Dermatol Venereol, 2019,33(2):325⁃332. doi: 10.1111/jdv.15287. |
[65] | Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin⁃23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52⁃week, phase 3, multicenter, open⁃label study[J]. J Dermatol, 2018,45(5):529⁃539. doi: 10.1111/1346⁃8138.14294. |
[66] | Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment[J]. Ann Rheum Dis, 2010,69(1):48⁃53. doi: 10.1136/ard.2008.102053. |
[67] | Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response[J]. J Rheumatol, 2014,41(6):1212⁃1217. doi: 10.3899/jrheum.140172. |
[68] | Tillett W, Eder L, Goel N, et al. Enhanced patient involvement and the need to revise the core set ⁃ report from the Psoriatic Arthritis Working Group at OMERACT 2014[J]. J Rheumatol, 2015,42(11):2198⁃2203. doi: 10.3899/jrheum.141156. |
[69] | Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update[J]. Ann Rheum Dis, 2016,75(3):499⁃510. doi: 10.1136/annrheumdis⁃2015⁃208337. |
[70] | Mikhaylov D, Hashim PW, Nektalova T, et al. Systemic psoriasis therapies and comorbid disease in patients with psoriasis: a review of potential risks and benefits[J]. J Clin Aesthet Dermatol, 2019,12(6):46⁃54. |
[71] | 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南(2021)[J]. 中华皮肤科杂志, 2021,54(12):1033⁃1047. doi: 10.35541/cjd.20210643. |
[72] | Owczarek W, Walecka I, Lesiak A, et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines[J]. Postepy Dermatol Alergol, 2020,37(6):821⁃830. doi: 10.5114/ada.2020.102089. |
[73] | Balakirski G, Gerdes S, Beissert S, et al. Therapy of psoriasis during pregnancy and breast⁃feeding[J]. J Dtsch Dermatol Ges, 2022,20(5):653⁃683. doi: 10.1111/ddg.14789. |
[74] | Peris K, Fortina AB, Bianchi L, et al. Update on the management of pediatric psoriasis: an Italian consensus[J]. Dermatol Ther (Heidelb), 2022,12(8):1753⁃1775. doi: 10.1007/s13555⁃022⁃00758⁃2. |
[75] | Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics[J]. J Am Acad Dermatol, 2020,82(1):213⁃221. doi: 10.1016/j.jaad.2019.05.056. |
[76] | Sandhu VK, Ighani A, Fleming P, et al. Biologic treatment in elderly patients with psoriasis: a systematic review[J]. J Cutan Med Surg, 2020,24(2):174⁃186. doi: 10.1177/1203475419897 578. |
[77] | Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0[J]. J Am Acad Dermatol, 2012,67(5):1025⁃1039. doi: 10.1016/j.jaad.2012.02. 010. |
[78] | Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis[J]. N Engl J Med, 2021,385(2):142⁃152. doi: 10.1056/NEJMoa2102383. |
[79] | Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate⁃to⁃severe psoriasis in adults[J]. J Eur Acad Dermatol Venereol, 2019,33(3):464⁃483. doi: 10.1111/jdv.15340. |
[80] | Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta⁃analysis[J]. JAMA Dermatol, 2020,156(3):258⁃269. doi: 10.1001/jamadermatol.2019.4029. |
[81] | Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council[J]. J Am Acad Dermatol, 2020,82(1):117⁃122. doi: 10.1016/j.jaad.2019.08.026. |
[82] | Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update[J]. Br J Dermatol, 2020,183(4):628⁃637. doi: 10.1111/bjd.19039. |
[83] | Huang H, Cai ML, Hong XJ, et al. Real⁃world data on the use of secukinumab as treatment for moderate⁃to⁃severe psoriasis in Chinese patients[J]. Eur J Dermatol, 2020,30(5):554⁃560. doi: 10.1684/ejd.2020.3878. |
[84] | Ruan SF, Zhang LL, Liu Z, et al. Real⁃world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: a 48⁃week retrospective study[J]. J Am Acad Dermatol, 2023,88(1):243⁃246. doi: 10.1016/j.jaad.2022.04.064. |
[85] | Ye LR, Yan BX, Chen XY, et al. Extended dosing intervals of ixekizumab for psoriasis: a single⁃center, uncontrolled, prospective study[J]. J Am Acad Dermatol, 2022,86(6):1348⁃1350. doi: 10.1016/j.jaad.2021.04.093. |
[86] | Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial[J]. Lancet, 2000,356(9227):385⁃390. doi: 10.1016/S0140⁃6736(00)02530⁃7. |
[87] | Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phase III, multicentre, double⁃blind trial[J]. Lancet, 2005,366(9494):1367⁃1374. doi: 10.1016/S0140⁃6736(05)67566⁃6. |
[88] | Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)[J]. Br J Dermatol, 2008,158(3):558⁃566. doi: 10.1111/j.1365⁃2133.2007.08315.x. |
[89] | Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis⁃⁃results of two phase 3 trials[J]. N Engl J Med, 2014,371(4):326⁃338. doi: 10.1056/NEJMoa1314258. |
[90] | Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate⁃to⁃severe plaque psoriasis[J]. N Engl J Med, 2016,375(4):345⁃356. doi: 10.1056/NEJMoa1512711. |
[91] | Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 76⁃week results from a randomised, double⁃blind, placebo⁃controlled trial (PHOENIX 1)[J]. Lancet, 2008,371(9625):1665⁃1674. doi: 10.1016/S0140⁃6736(08)60725⁃4. |
[92] | Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial[J]. Lancet, 2019,394(10201):831⁃839. doi: 10.1016/S0140⁃6736(19)31773⁃8. |
[93] | Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies[J]. J Am Acad Dermatol, 2020,82(6):1445⁃1486. doi: 10.1016/j.jaad.2020.02.044. |
[94] | Dogra S, Jain A, Kanwar AJ. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study[J]. 2013,27(3):e305⁃311. |
[95] | Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial[J]. J Am Acad Dermatol, 2008,58(1):106⁃115. doi: 10.1016/j.jaad.2007.09.010. |
[96] | Tsai YC, Tsai TF. Switching biologics in psoriasis ⁃ practical guidance and evidence to support[J]. Expert Rev Clin Pharmacol, 2020,13(5):493⁃503. doi: 10.1080/17512433.2020. 1767590. |
[97] | Zhao S, Xie B, Li Y, et al. Smart identification of psoriasis by images using convolutional neural networks: a case study in China[J]. J Eur Acad Dermatol Venereol, 2020,34(3):518⁃524. doi: 10.1111/jdv.15965. |
[98] | Cao D, Shen M, Chen X, et al. Validation of a simple measure of psoriasis severity based on a longitudinal study of Chinese patients[J]. Eur J Dermatol, 2020,30(6):674⁃679. doi: 10. 1684/ejd.2020.3914. |
[1] | 中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识(2023)[J]. 中华皮肤科杂志, 2023, 0(4): 20220819-e20220819. |
[2] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识(2023)[J]. 中华皮肤科杂志, 2023, 0(4): 20230004-e20230004. |
[3] | 阮诗钒 张鹏 林婷婷 罗仁炜 鲍思怡 薛晨瑶 童泽群 张亮亮 龚婷 纪超. 寻常型银屑病与血脂异常的相关性研究[J]. 中华皮肤科杂志, 2023, 0(3): 20220322-e20220322. |
[4] | 周健 俞晨 王刚. 司库奇尤单抗治疗13例难治性局限性脓疱型银屑病的临床疗效与安全性观察[J]. 中华皮肤科杂志, 2023, 56(3): 247-251. |
[5] | 胡琨 杨晶 王巧林 陈军臣 张谧 朱武 张斌 窦冠珅 Wendong Chen, 匡叶红. [开放获取] 依奇珠单抗治疗银屑病短期疗效的单中心病例回顾性研究[J]. 中华皮肤科杂志, 2023, 56(3): 210-215. |
[6] | 罗帅寒天 龙海 陆前进. 2022年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2023, 56(3): 266-269. |
[7] | 陈奇权 杨显杰 顾恒 徐金华 郝飞 姚煦 宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹专家诊治共识(2023)》[J]. 中华皮肤科杂志, 2023, 0(3): 20220814-e20220814. |
[8] | 何谐 栗玉珍. 靶向JAK-STAT信号通路治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(3): 273-278. |
[9] | 苑辰 闫言 王宝玺. 反常性痤疮的生物治疗进展[J]. 中华皮肤科杂志, 2023, 56(3): 270-273. |
[10] | 王召阳 向欣 陈云刘 苗朝阳 赵欣荣 张振华 刘元香 马琳 徐子刚. 生物制剂与甲氨蝶呤治疗儿童重度斑块状银屑病疗效及安全性比较[J]. 中华皮肤科杂志, 2023, 56(2): 112-117. |
[11] | 贾元源 毛秋雨 杨婧怡 闵玮. 度普利尤单抗治疗中重度老年特应性皮炎临床疗效观察[J]. 中华皮肤科杂志, 2023, 56(2): 125-129. |
[12] | 中华医学会皮肤性病学分会 中国康复医学会皮肤病康复专业委员会 中国中西医结合学会皮肤性病学分会 中国医药教育协会皮肤病专业委员会. 老年带状疱疹诊疗专家共识[J]. 中华皮肤科杂志, 2023, 56(2): 97-104. |
[13] | 杨琦 郑捷. 生物制剂治疗对银屑病相关心血管疾病的影响[J]. 中华皮肤科杂志, 2023, 56(2): 165-169. |
[14] | 黄贺 张学军. 白细胞介素23抑制剂古塞奇尤单抗在银屑病治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(2): 181-184. |
[15] | 田晶 梁源 马琳. 度普利尤单抗治疗儿童特应性皮炎的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210730-e20210730. |
|